Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -46.45K | -12.18K | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | -24.23M | -12.25M | -5.45M | -12.32M | -15.64M | -10.01M |
Net Income | -24.74M | -12.35M | -5.30M | -12.25M | -15.96M | -10.35M |
Balance Sheet | ||||||
Total Assets | 96.69M | 94.31M | 4.17M | 8.37M | 15.78M | 31.47M |
Cash, Cash Equivalents and Short-Term Investments | 13.40M | 14.85M | 3.32M | 7.03M | 14.01M | 29.80M |
Total Debt | 75.85M | 15.59M | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 89.81M | 30.03M | 358.55K | 1.04M | 1.28M | 1.53M |
Stockholders Equity | 14.15M | 64.28M | 3.81M | 7.33M | 14.50M | 29.94M |
Cash Flow | ||||||
Free Cash Flow | -15.75M | -8.79M | -4.87M | -11.47M | -15.69M | -3.90M |
Operating Cash Flow | -15.75M | -8.79M | -4.87M | -11.47M | -15.69M | -3.90M |
Investing Cash Flow | 3.76M | 3.76M | 0.00 | 0.00 | 0.00 | 0.00 |
Financing Cash Flow | 22.50M | 16.70M | 1.16M | 4.49M | -97.60K | 33.38M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.90B | -0.33 | -41.69% | 2.23% | 23.45% | -1.99% | |
49 Neutral | $9.48M | ― | -494.11% | ― | ― | -219.97% | |
46 Neutral | $17.37M | ― | -321.37% | ― | 4455.07% | 77.31% | |
44 Neutral | $18.39M | ― | -362.79% | ― | -48.01% | 33.60% | |
― | $6.33M | 0.36 | 67.08% | ― | ― | ― | |
40 Underperform | $9.15M | ― | -67.54% | ― | -34.07% | 23.79% | |
39 Underperform | $6.91M | ― | -285.93% | ― | ― | 53.79% |
On March 12, 2025, Dogwood Therapeutics entered into a Debt Exchange and Cancellation Agreement with Conjoint Inc., converting $19.5 million in debt into equity by issuing Series A-1 Non-Voting Convertible Preferred Stock. This strategic move, supported by the company’s largest shareholder CK Life Sciences Int’l., strengthens Dogwood’s balance sheet and underscores confidence in its lead product, Halneuron®, which is being developed as a non-opioid pain treatment. The agreement allows Dogwood to focus on its Phase 2b clinical trial for chemotherapy-induced neuropathic pain without the burden of debt, potentially enhancing its attractiveness to investors.